Full Text Journal Articles by
Author Lianchun Xiao

Advertisement

Find full text journal articles






HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk.

Jeffrey S Morris, Manal M Hassan, Ye Emma Zohner, Zeya Wang, Lianchun Xiao, Asif Rashid, Abedul Haque, Reham Abdel-Wahab, Yehia I Mohamed, Karri L Ballard, Robert A Wolff, Bhawana George, Liang Li, Genevera Allen, Michael Weylandt, Donghui Li, Wenyi Wang, Kanwal Raghav, James Yao, Hesham M Amin, Ahmed Omar Kaseb,

<h4>Background and aims</h4>Therapeutic, clinical trial entry and stratification decisions for hepatocellular carcinoma (HCC) are made based on prognostic assessments, using clinical staging systems based on small numbers of empirically selected variables that insufficiently account for differences in biological characteristics of individual patients' disease.<h4>Approach and results</h4>We propose an approach for constructing ... Read more >>

Hepatology (Hepatology (Baltimore, Md.))
[2021, 73(6):2278-2292]

Cited: 1 time

View full text PDF listing >>



Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer.

Yoshikuni Kawaguchi, Scott Kopetz, Lawrence Kwong, Lianchun Xiao, Jeffrey S Morris, Hop S Tran Cao, Ching-Wei D Tzeng, Yun Shin Chun, Jeffrey E Lee, Jean-Nicolas Vauthey,

<h4>Background</h4>An understanding of signaling pathways has not been fully incorporated into prognostication and therapeutic options. We evaluated the hypothesis that information about cancer-related signaling pathways can improve prognostic stratification and explain some of the clinical heterogeneity in patients with metastatic colorectal cancer.<h4>Study design</h4>We analyzed prognostic relevance of signaling pathways in ... Read more >>

J Am Coll Surg (Journal of the American College of Surgeons)
[2021, 233(2):272-284.e13]

Cited: 0 times

View full text PDF listing >>



Advertisement

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.

Courtney D DiNardo, Curtis A Lachowiez, Koichi Takahashi, Sanam Loghavi, Lianchun Xiao, Tapan Kadia, Naval Daver, Maria Adeoti, Nicholas J Short, Koji Sasaki, Sa Wang, Gautam Borthakur, Ghayas Issa, Abhishek Maiti, Yesid Alvarado, Naveen Pemmaraju, Guillermo Montalban Bravo, Lucia Masarova, Musa Yilmaz, Nitin Jain, Michael Andreeff, Elias Jabbour, Guillermo Garcia-Manero, Steven Kornblau, Farhad Ravandi, Marina Y Konopleva, Hagop M Kantarjian,

<h4>Purpose</h4>Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients relapse. Relapsed or refractory AML (R/R-AML) remains a particularly adverse population necessitating improved therapeutic options. This phase Ib/II study evaluated the safety and efficacy of fludarabine, cytarabine, ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2021, :JCO2003736]

Cited: 0 times

View full text PDF listing >>



Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.

Milind Javle, Einat Shacham-Shmueli, Lianchun Xiao, Gauri Varadhachary, Naama Halpern, David Fogelman, Ben Boursi, Syeda Uruba, Ofer Margalit, Robert A Wolff, Talia Golan,

<h4>Importance</h4>The subtype of pancreatic ductal adenocarcinoma cancer (PDAC) with DNA damage repair (DDR) deficiency from BRCA1/2 variants has a favorable prognosis and is sensitive to platinum analogues and poly-(adenosine diphosphate-ripose) polymerase (PARP) inhibition with olaparib. Approximately 10% to 20% of patients with PDAC have DDR genetic alterations other than germline ... Read more >>

JAMA Oncol (JAMA oncology)
[2021, 7(5):693-699]

Cited: 1 time

View full text PDF listing >>



Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.

Andrew J Wiele, Tharakeswara K Bathala, Andrew W Hahn, Lianchun Xiao, Munevver Duran, Jeremy A Ross, Eric Jonasch, Amishi Y Shah, Matthew T Campbell, Pavlos Msaouel, Nizar M Tannir,

<h4>Introduction</h4>Lenvatinib (Len) plus everolimus (Eve) is an approved therapy for metastatic renal cell carcinoma (mRCC) after first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), but limited data exist on the efficacy of Len ± Eve after progression on immune checkpoint inhibitors (ICIs) and VEGFR-TKIs.<h4>Methods</h4>We retrospectively reviewed the records of ... Read more >>

Oncologist (The oncologist)
[2021, 26(6):476-482]

Cited: 1 time

View full text PDF listing >>



A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.

Mahesh Swaminathan, Hagop M Kantarjian, Mark Levis, Veronica Guerra, Gautam Borthakur, Yesid Alvarado, Courtney D DiNardo, Tapan Kadia, Guillermo Garcia-Manero, Maro Ohanian, Naval Daver, Marina Konopleva, Naveen Pemmaraju, Alessandra Ferrajoli, Michael Andreeff, Nitin Jain, Zeev Estrov, Elias J Jabbour, William G Wierda, Sherry Pierce, Maria Rhona Pinsoy, Lianchun Xiao, Farhad Ravandi, Jorge E Cortes,

FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in acute myeloid leukemia (AML) is associated with poor prognosis. We hypothesized that quizartinib, a selective and potent FLT3 inhibitor, with azacitidine (AZA) or low-dose cytarabine (LDAC) might improve the outcomes in patients with FLT3-ITD-mutated AML. In this open-label phase I/II trial, ... Read more >>

Haematologica (Haematologica)
[2021, :]

Cited: 2 times

View full text PDF listing >>



Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.

Yehia I Mohamed, Sunyoung Lee, Lianchun Xiao, Manal M Hassan, Aliya Qayyum, Rikita Hiatia, Roberto Carmagnani Pestana, Abedul Haque, Bhawana George, Asif Rashid, Dan G Duda, Hesham Elghazaly, Robert A Wolff, Jeffrey S Morris, James Yao, Hesham M Amin, Ahmed O Kaseb,

<h4>Background</h4>Sorafenib was the first systemic therapy approved for the treatment of Child-Turcotte-Pugh (CTP) class A patients with advanced hepatocellular carcinoma (HCC). However, there are no biomarkers to predict survival and treatment outcomes and guide HCC systemic therapy. Type 1 insulin-like growth factor (IGF-1)/CTP composite score has emerged as a potential ... Read more >>

Oncotarget (Oncotarget)
[2021, 12(8):756-766]

Cited: 0 times

View full text PDF listing >>



Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.

Caitlin R Rausch, Courtney D DiNardo, Abhishek Maiti, Nadya J Jammal, Tapan M Kadia, Kayleigh R Marx, Gautam Borthakur, J Michael Savoy, Naveen Pemmaraju, Adam J DiPippo, Naval G Daver, Serena M Chew, Koji Sasaki, Ghayas C Issa, Nicholas J Short, Koichi Takahashi, Maro N Ohanian, Jing Ning, Lianchun Xiao, Yesid Alvarado, Dimitrios P Kontoyiannis, Farhad Ravandi, Hagop M Kantarjian, Marina Y Konopleva,

<h4>Background</h4>Venetoclax (VEN) combined with the hypomethylating agent (HMA) azacitidine improves survival in patients aged ≥75 years with newly diagnosed acute myeloid leukemia (AML). VEN and HMA treatment can result in prolonged and often profound neutropenia, and this warrants antifungal prophylaxis. Azole antifungals inhibit cytochrome P450 3A4, the primary enzyme responsible ... Read more >>

Cancer (Cancer)
[2021, 127(14):2489-2499]

Cited: 0 times

View full text PDF listing >>



Impact of Definitive Local Therapy in Men with Primary Small Cell Prostate Carcinoma.

Oluchi Oke, Weranja Ranasinghe, Chad Tang, Sherif Shaaban, Lianchun Xiao, Chad A Reichard, Mitchell Steven Anscher, Brian Francis Chapin, Ana Aparicio,

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study.

Patrick K Reville, Hagop M Kantarjian, Farhad Ravandi, Elias Jabbour, Courtney D DiNardo, Naval Daver, Naveen Pemmaraju, Maro Ohanian, Yesid Alvarado, Lianchun Xiao, Gheath Alatrash, Sanam Loghavi, Caitlin R Rausch, Gautam Borthakur, Marina Konopleva, Jorge Cortes, Tapan M Kadia,

Blood Cancer J (Blood cancer journal)
[2021, 11(3):60]

Cited: 0 times

View full text PDF listing >>



Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.

Andrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, Minas Economides, Aradhana Venkatesan, Jianjun Gao, Eric Jonasch, Paul Corn, Amado Zurita-Saavedra, Landon C Brown, Chester Kao, Emily N Kinsey, Rajan T Gupta, Michael R Harrison, Andrew J Armstrong, Daniel J George, Nizar Tannir, Pavlos Msaouel, Amishi Shah, Tian Zhang, Matthew T Campbell,

<h4>Introduction</h4>Two separate antiangiogenic tyrosine kinase inhibitors (TKIs) and immunotherapy (IO) combinations are FDA-approved as front-line treatment for metastatic renal cell carcinoma (mRCC). Little is known about off-protocol and post-front-line experience with combination TKI-IO approaches.<h4>Methods</h4>We conducted a retrospective analysis of mRCC patients who received combination TKI-IO post-first-line therapy between November 2015 ... Read more >>

Cancer Med (Cancer medicine)
[2021, 10(7):2341-2349]

Cited: 0 times

View full text PDF listing >>



Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma.

Shumei Song, Qiongrong Chen, Yuan Li, Guang Lei, Ailing Scott, Longfei Huo, Cordelia Y Li, Jeannelyn Santiano Estrella, Arlene Correa, Melissa Pool Pizzi, Lang Ma, Jiankang Jin, Bin Liu, Ying Wang, Lianchun Xiao, Wayne L Hofstetter, Jeffrey H Lee, Brian Weston, Manoop Bhutani, Namita Shanbhag, Randy L Johnson, Boyi Gan, Shaozhong Wei, Jaffer A Ajani,

<h4>Objective</h4>Gastro-oesophageal cancers (GEC) are resistant to therapy and lead to poor prognosis. The cancer stem cells (CSCs) and antiapoptotic pathways often confer therapy resistance. We sought to elucidate the antitumour action of a BCL-2 inhibitor, AT101 in GEC in vitro, in vivo and in a clinical trial.<h4>Methods</h4>Extensive preclinical studies in ... Read more >>

Gut (Gut)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.

Jad Chahoud, Pavlos Msaouel, Jeremy A Ross, Barrett Z McCormick, Tharakeswara K Bathala, Jianjun Gao, Robert Horn, Lianchun Xiao, Kanishka Sircar, Matthew T Campbell, Amishi Y Shah, Sangeeta Goswami, Amado J Zurita, Eric Jonasch, Surena F Matin, Christopher G Wood, Jose A Karam, Padmanee Sharma, Nizar M Tannir,

<h4>Introduction</h4>Metastatic renal cell carcinoma with sarcomatoid dedifferentiation (sRCC) is associated with poor survival outcomes. We aimed to analyze the efficacy and safety of immune checkpoint inhibitors (ICI) in patients with sRCC comparing clear-cell (sccRCC) to non-clear cell epithelial histology (snccRCC).<h4>Methods</h4>We performed retrospective analysis of sRCC patients who received ICI at ... Read more >>

Urol Oncol (Urologic oncology)
[2021, 39(2):134.e9-134.e16]

Cited: 0 times

View full text PDF listing >>



CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia.

Mariela Sivina, Lianchun Xiao, Ekaterina Kim, Alicia Vaca, Shih-Shih Chen, Michael J Keating, Alessandra Ferrajoli, Zeev Estrov, Nitin Jain, William G Wierda, Xuelin Huang, Nicholas Chiorazzi, Jan A Burger,

The chemoattractant CXCL13 organizes the cellular architecture of B-cell follicles and germinal centers. During adaptive immune responses, CXCL13 plasma concentrations transiently increase and function as a biomarker for normal germinal center activity. Chronic lymphocytic leukemia (CLL) cells express high levels of CXCR5, the receptor for CXCL13, and proliferate in pseudofollicles ... Read more >>

Leukemia (Leukemia)
[2021, 35(6):1610-1620]

Cited: 0 times

View full text PDF listing >>



Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients.

Reham Abdel-Wahab, Manal M Hassan, Bhawana George, Roberto Carmagnani Pestana, Lianchun Xiao, Sahin Lacin, Suayib Yalcin, Ahmed S Shalaby, Humaid O Al-Shamsi, Kanwal Raghav, Robert A Wolff, James C Yao, Lauren Girard, Abedul Haque, Dan G Duda, Simona Dima, Irinel Popescu, Hesham A Elghazaly, Jean-Nicolas Vauthey, Thomas A Aloia, Ching-Wei Tzeng, Yun Shin Chun, Asif Rashid, Jeffrey S Morris, Hesham M Amin, Ahmed O Kaseb,

<h4>Background</h4>Liver reserve affects survival in hepatocellular carcinoma (HCC). Model for End-Stage Liver Disease (MELD) score is used to predict overall survival (OS) and to prioritize HCC patients on the transplantation waiting list, but more accurate models are needed. We hypothesized that integrating insulin-like growth factor 1 (IGF-1) levels into MELD ... Read more >>

Oncology (Oncology)
[2020, 98(12):836-846]

Cited: 1 time

View full text PDF listing >>



Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality.

Ghayas C Issa, Hagop M Kantarjian, Lianchun Xiao, Jing Ning, Yesid Alvarado, Gautam Borthakur, Naval Daver, Courtney D DiNardo, Elias Jabbour, Prithviraj Bose, Nitin Jain, Tapan M Kadia, Kiran Naqvi, Naveen Pemmaraju, Koichi Takahashi, Srdan Verstovsek, Micheal Andreeff, Steven M Kornblau, Zeev Estrov, Alessandra Ferrajoli, Guillermo Garcia-Manero, Maro Ohanian, William G Wierda, Farhad Ravandi, Jorge E Cortes,

CPX-351 is a liposomal formulation of cytarabine/daunorubicin with a 5:1 fixed molar ratio. We investigated the safety and efficacy of escalating doses of CPX-351 in patients with acute myeloid leukemia (AML) at high risk of induction mortality with standard chemotherapy determined through assessment of leukemia and patient-related risk factors for ... Read more >>

Leukemia (Leukemia)
[2020, 34(11):2914-2924]

Cited: 1 time

View full text PDF listing >>



Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma.

Jane E Rogers, Jonathan D Mizrahi, Lianchun Xiao, Chirayu Mohindroo, Rachna T Shroff, Robert Wolff, Gauri R Varadhachary, Milind M Javle, Michael Overman, David R Fogelman, Kanwal P S Raghav, Shubham Pant, Florencia McAllister,

<h4>Background</h4>Gemcitabine (GEM) plus nab-paclitaxel (NabP) (GEM 1000 mg/m<sup>2</sup> IV over 30 minutes + NabP 125 mg/m<sup>2</sup> IV given days 1, 8, and 15 every 28 days) is one of the two standard of care combination therapies for metastatic pancreatic ductal adenocarcinoma (PDAC). Our cancer center has utilized GEM-NabP given every two-weeks due to tolerability and patient ... Read more >>

Cancer Med (Cancer medicine)
[2020, 9(15):5406-5415]

Cited: 2 times

View full text PDF listing >>



Spine stereotactic radiosurgery for metastases from hepatobiliary malignancies: patient selection using PRISM scoring.

Olsi Gjyshi, David Boyce-Fappiano, Todd A Pezzi, Ethan B Ludmir, Lianchun Xiao, Ahmed Kaseb, Behrang Amini, Debra Nana Yeboa, Andrew J Bishop, Jing Li, Laurence D Rhines, Claudio Esteves Tatsui, Tina Marie Briere, Amol Jitendra Ghia,

<h4>Objective</h4>Dose escalation via stereotactic radiation therapy techniques has been necessary for hepatobiliary malignancies in the primary and oligometastatic setting, but such dose escalation is challenging for spine metastases due to spinal cord proximity. Here, we investigate the role of spine stereotactic radiosurgery (SSRS) in the management of such metastases.<h4>Methods</h4>We retrospectively ... Read more >>

J Neurooncol (Journal of neuro-oncology)
[2020, 148(2):327-334]

Cited: 1 time

View full text PDF listing >>



A prospective parallel design study testing non-inferiority of customized oral stents made using 3D printing or manually fabricated methods.

Mohamed Zaid, Eugene J Koay, Nimit Bajaj, Ryan Mathew, Lianchun Xiao, Anshuman Agrawal, Pearl Fernandes, Hannah Burrows, Millicent A Roach, Christopher T Wilke, Caroline Chung, Clifton D Fuller, Jack Phan, G Brandon Gunn, William H Morrison, Adam S Garden, Steven J Frank, David I Rosenthal, Michael Andersen, Adegbenga Otun, Mark S Chambers,

<h4>Background and purpose</h4>Customized mouth-opening-tongue-depressing-stents (MOTDs) may reduce toxicity in patients with head and neck cancers (HNC) receiving radiotherapy (RT). However, making MOTDs requires substantial resources, which limits their utilization. Previously, we described a workflow for fabricating customized 3D-printed MOTDs. This study reports the results of a prospective trial testing the ... Read more >>

Oral Oncol (Oral oncology)
[2020, 106:104665]

Cited: 0 times

View full text PDF listing >>



Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer.

Jane E Rogers, Lianchun Xiao, Allison Trail, Mariela Blum Murphy, Melissa Palmer, Jaffer A Ajani,

<h4>Introduction</h4>Advanced unresectable gastroesophageal cancers continue to confer a dismal patient prognosis. Limited options remain once the cancer is refractory to cytotoxics/biologics (like irinotecan, taxane, and ramucirumab). Recently, anti-programmed death-1 (anti-PD-1) inhibitors have been used with limited efficacy in select patients with adenocarcinoma. Similarly, irinotecan-based therapy has marginal efficacy. We combined ... Read more >>

Oncology (Oncology)
[2020, 98(5):289-294]

Cited: 1 time

View full text PDF listing >>



Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.

Michael Overman, Milind Javle, Richard E Davis, Pankaj Vats, Chandan Kumar-Sinha, Lianchun Xiao, Niharika B Mettu, Edwin R Parra, Al B Benson, Charles D Lopez, Veerendra Munugalavadla, Priti Patel, Lin Tao, Sattva Neelapu, Anirban Maitra,

<h4>Background</h4>The immunosuppressive desmoplastic stroma of pancreatic cancer represents a major hurdle to developing an effective immune response. Preclinical studies in pancreatic cancer have demonstrated promising anti-tumor activity with Bruton tyrosine kinase (BTK) inhibition combined with programmed cell death receptor-1 (PD-1) blockade.<h4>Methods</h4>This was a phase II, multicenter, open-label, randomized (1:1) clinical ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2020, 8(1):]

Cited: 14 times

View full text PDF listing >>



A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer.

Paul G Corn, Miao Zhang, Graciela M Nogueras-Gonzalez, Lianchun Xiao, Amado J Zurita, Sumit K Subudhi, Shi-Ming Tu, Ana M Aparicio, Cristian Coarfa, Kimal Rajapakshe, Shixia Huang, Nora M Navone, Sue-Hwa Lin, Guocan Wang, Sumankalai Ramachandran, Mark A Titus, Theocharis Panaretakis, Gary E Gallick, Eleni Efstathiou, Patricia Troncoso, Christopher Logothetis,

<h4>Purpose</h4>Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy (ADT) in hormone-naïve metastatic prostate cancer (HNMPCa).<h4>Patients and methods</h4>Patients received ADT plus cabozantinib starting at 60 mg daily. The primary endpoint was ... Read more >>

Clin Cancer Res (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2020, 26(5):990-999]

Cited: 0 times

View full text PDF listing >>



Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers.

Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai,

<h4>Background</h4>Gemcitabine plus platinum is the standard of care first-line treatment for advanced biliary tract cancers (BTC). There is no established second-line therapy, and retrospective reviews report median progression-free survival (PFS) less than 3 mo on second-line therapy. 5-Fluorouracil plus irinotecan (FOLFIRI) is a commonly used regimen in patients with BTC ... Read more >>

World J Gastrointest Oncol (World journal of gastrointestinal oncology)
[2020, 12(1):83-91]

Cited: 0 times

View full text PDF listing >>



Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait.

Ryan W Huey, Shalini Makawita, Lianchun Xiao, Aurelio Matamoros, Jeannelyn S Estrella, Michael J Overman, Gauri R Varadhachary, Kanwal Raghav,

BACKGROUND:Sarcomatoid carcinoma of unknown primary (SCUP) is a rare entity of either poorly differentiated carcinoma with sarcoma-like differentiation or a true mixed lineage neoplasm. Limited data regarding clinicopathological profile and management exists. METHODS:We retrospectively reviewed the MD Anderson Cancer of Unknown Primary database and tumor registry to identify 48 SCUP ... Read more >>

BMC Cancer (BMC cancer)
[2019, 19(1):965]

Cited: 6 times

View full text PDF listing >>



Supports and Barriers to Home-Based Physical Activity During Preoperative Treatment of Pancreatic Cancer: A Mixed-Methods Study.

Nathan H Parker, Rebecca E Lee, Daniel P O'Connor, An Ngo-Huang, Maria Q B Petzel, Keri Schadler, Xuemei Wang, Lianchun Xiao, David Fogelman, Richard Simpson, Jason B Fleming, Jeffrey E Lee, Ching-Wei D Tzeng, Sunil K Sahai, Karen Basen-Engquist, Matthew H G Katz,

<h4>Background</h4>Physical activity and exercise appear to benefit patients receiving preoperative treatment for cancer. Supports and barriers must be considered to increase compliance with home-based exercise prescriptions in this setting. Such influences have not been previously examined.<h4>Methods</h4>The authors used quantitative and qualitative methods to examine potential physical activity influences among patients ... Read more >>

J Phys Act Health (Journal of physical activity & health)
[2019, 16(12):1113-1122]

Cited: 3 times

View full text PDF listing >>



Advertisement

Disclaimer
1.097 s